NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

Size: px
Start display at page:

Download "NICE TA Adherence Check list April Drug Indication NICE Approval Release Date"

Transcription

1 NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide intravitreal implant Peginterferon alfa and ribavirin Lung cancer (non small cell, EGFR mutation positive) Vasculitis(anti-netrophil cytoplasmic antibodyassociated) monotherapy for treating multiply relapsed or refractory aggressive non- Hodgkin's B cell lymphoma macular oedema secondary to central retinal vein occlusion relapsing remitting multiple sclerosis TA311 TA310 TA308 TA306 TA305 TA303 23/4/2014 Yes 23/4/2014 Yes 26/3/2014 Yes 26/02/2014 Yes 26/02/2014 Yes 22/01/2014 Yes Diabetic macular oedema TA301 27/11/2013 yes chronic hepatitis C in children and young people TA300 27/11/2013 Yes Ranibizumab choroidal neovascularisation TA298 27/11/2013 Yes associated with pathological myopia Ocriplasmin Vitreomacular Traction TA297 23/10/2013 Yes for local use Aflibercept ( Eylea) Wet-age related Macular degeneration TA294 24/07/2013 Yes Eltrombopag Idiopathic thrombocytopenia purpura TA293 24/07/2013 Yes Aripiprazole (oral) Bipolar Disorder (children 13yrs & over) TA292 24/07/2013 Yes Mirabegron Overactive Bladder TA290 26/06/2013 Yes Dapagliflozin Combination thearpy Rivaroxaban Type2 diabetes TA288 26/06/2013 Yes Pulmonary embolism & preventing recurrent venous thromboembolism TA287 26/06/2013 Yes

2 Ranibizumab visual impairment caused by macular oedema secondary to retinal veil occlusion TA283 22/05/2013 Yes Kyphoplasty Vertebral Fractures TA279 25/04/2013 Yes Pirfenidone Idiopathic pulmonary fibrosis TA282 24/04/2013 Yes Abatacept RA (first TNF) TA280 24/04/2013 Yes Vertebroplasty Vertebral Fractures TA279 24/04/2013 Yes Omalizumab Asthma - over 12yo & adults TA278 24/04/2013 Yes Omalizumab Asthma yo TA278 24/04/2013 Yes Colistimethate Cystic Fibrosis TA276 27/03/2013 Yes Sodium (pseudomonas lung infection) Tobramycin Cystic Fibrosis TA276 27/03/2013 Yes (pseudomonas lung infection) Ranibizumab Diabetic macular oedema TA274 27/02/2013 Yes Apixaban Stroke & Systemic embolism TA275 27/02/2013 Yes Verumafenib Locally Adv. Or metastatic TA269 12/12/2012 Yes BRAF V600 mutationpositive unresectable metastatic Ipilimumab Metastatic melanoma TA268 12/12/2012 Yes Ivabradine Heart Failure II - IV TA267 28/11/2012 Yes Mannitol Cystic Fibrosis TA266 28/11/2012 Yes Botulinum toxin A Chronic migraine TA260 27/11/2012 Yes Denosumab Bone Metastases for solid tumours TA265 24/10/2012 Yes

3 Alteplase Acute ischaemic stoke TA264 26/09/2012 Yes Rivaroxaban deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism TA261 25/07/2012 Yes Abiraterone (Zytiga) Metastatic Castration resistant Prostate Ca TA259 27/06/2012 Yes Erlotinib NSCLC with EGFR activating mutations TA258 27/06/2012 Yes Rivaroxaban Stroke prevention in AF TA256 23/05/2012 Yes Bocepravir Telaprevir Genotype 1 chronic Hepatitis C Genotype 1 chronic Hepatitis C TA253 TA252 25/04/2012 Yes 25/04/2012 Yes Fingolimod highly active relapsing remitting multiple sclerosis (In Adults) TA254 25/04/2012 Yes Dabigatran Stroke prevention in AF TA249 15/03/2012 Yes etexilate Exenatide LAR Type 2 diabetes TA248 22/02/2012 Yes Pharmalgen Hypersensitivity to bee & TA246 22/02/2012 Yes wasp venom Tocilizumab Rheumatoid arthritis TA247 22/02/2012 Yes Apixaban Rituximab Prevention of VT after total Hip or Knee replacement in Adults 1st line Treatment of Follicular Lymphoma stages III - IV TA245 TA243 25/01/2012 Yes 25/01/2012 Yes Roflumilast COPD TA244 25/01/2012 Yes

4 Cyclophosphamide Follicular lymphoma TA243 25/01/2012 Yes Nilotinib Tocilizumab CML dasatinib, nilotinib, imatinib (intolerant, resistant) Juvenile Idiopathic systemic arthritis TA241 TA238 13/01/2012 Yes 14/12/2011 Yes Ticagrelor ACS TA236 26/10/2011 Yes Mifamurtide Osteosarcoma TA235 26/10/2011 Yes Golimumab Ankylosing spondylitis TA233 24/08/2011 Yes Retigabine Partial onset seizures TA232 27/07/2011 Yes Bivalirudin STEMI undergoing primary TA230 27/07/2011 Yes PCI Dexamethasone implant (Ozurdex) Macular oedema associated with retinal vein occlusion TA229 27/07/2011 Yes Bortezomib Multiple Myeloma (1st line) TA228 27/07/2011 Yes Thalidomide Mulitple myeloma (1st line) TA228 27/07/2011 Yes Rituximab Follicular NHL (maintenance) TA226 22/06/2011 Yes Golimumab Naftidrofuryl oxalate Romiplostim Rheumatoid arthritis (2nd line ) Intermiittent claudication associated with peripheral vasular disease Idiopathic thrombocytopenia purpura TA225 22/06/2011 Yes TA223 25/05/2011 Yes TA221 27/04/2011 Yes

5 Golimumab Psoriatic arthritis TA220 27/04/2011 Yes Rivastigmine Alzheimer's disease TA217 23/03/2011 Yes Rivastigmine (patch) Alzheimer's disease TA217 23/03/2011 Yes Donepezil Alzheimer's disease TA217 23/03/2011 Yes Galantamine Alzheimer's disease TA217 23/03/2011 Yes Azacitidine Myelodysplastic syndrome TA218 23/03/2011 Yes Memantine Alzheimer's disease TA217 23/03/2011 Yes Bendamustine CLL (1st line) TA216 23/02/2011 Yes Pazopanib Metastatic renal cell Ca (1st line) TA215 23/02/2011 Yes Aripiprazole (oral) Schizophrenia (15-17yo) TA213 26/01/2011 Yes Raloxifene Secondary prevention of TA161 26/01/2011 Yes osteoporosis Teriparatide Osteoporosis TA161 26/01/2011 Yes Alendronate Secondary prevention TA161 26/01/2011 Yes Etidronate Secondary prevention TA161 26/01/2011 Yes Risedronate Secondary prevention TA161 26/01/2011 Yes Strontium ranelate Secondary prevention TA161 26/01/2011 Yes Alendronate Primary prevention TA160 26/01/2011 Yes Etidronate Primary prevention TA160 26/01/2011 Yes Risedronate Primary prevention TA160 26/01/2011 Yes Strontium ranelate Primary prevention TA160 26/01/2011 Yes Prucalopride Refractory constipation in TA211 15/12/2010 Yes women Clopidogrel Occlusive vascular events TA210 15/12/2010 Yes Dipyridamole (MR) Occlusive vascular events TA210 15/12/2010 Yes

6 Imatinib Unresectable/metastatic TA86 24/11/2010 Yes GIST Imatinib Unresectable/metastatic GIST TA209 24/11/2010 Yes Denosumab Post-menopausal TA204 27/10/2010 Yes osteoporosis Liraglutide Type 2 diabetes TA203 27/10/2010 Yes Adalimumab Psoriatic arthritis TA199 25/08/2010 Yes Etanercept Psoriatic arthritis TA199 25/08/2010 Yes Infliximab Psoriatic arthritis TA199 25/08/2010 Yes Dronedarone AF TA197 25/08/2010 Yes Abatacept RA (after failure of TNF) TA195 25/08/2010 Yes Adalimumab RA (after failure of TNF) TA195 25/08/2010 Yes Etanercept RA (after failure of TNF) TA195 25/08/2010 Yes Infliximab RA (after failure of TNF) TA195 25/08/2010 Yes Rituximab RA (after failure of TNF) TA195 25/08/2010 Yes Capecitabine Advanced gastric Ca TA191 28/07/2010 Yes Gefitinib Gefitinib Rituximab in combination with fludarabine & cyclophosphamide Locally-advanced or TA192 28/07/2010 Yes metastatic NSCLC (1st line) Locally-advanced or TA192 28/07/2010 Yes metastatic NSCLC (1st line) CLL (relapsed or refractory) TA193 28/07/2010 Yes Pemetrexed NSCLC (maintenance) TA190 23/06/2010 Yes Somatropin Growth failure in children TA188 26/05/2010 Yes Adalimumab Crohn's disease TA187 19/05/2010 Yes Infliximab Crohn's disease TA187 19/05/2010 Yes Certolizumab pegol Rheumatoid arthritis TA186 24/02/2010 Yes Trabectedin Advanced soft tissue sarcoma TA185 24/02/2010 Yes

7 Topotecan (oral) Relapsed SCLC TA184 25/11/2009 Yes Cisplatin (in Cervical Ca TA183 28/10/2009 Yes combination) Topotecan Cervical Ca TA183 28/10/2009 Yes Prasugrel ACS TA182 28/10/2009 Yes Pemetrexed NSCLC (1st line) TA181 23/09/2009 Yes Ustekinumab Psoriasis TA180 23/09/2009 Yes Sunitinib GIST TA179 23/09/2009 Yes Alitretinoin Chronic hand eczema TA177 26/08/2009 Yes Cetuximab Metastatic colorectal Ca (1st line) TA176 26/08/2009 Yes Fluorouracil Colorectal Ca (first line) TA176 26/08/2009 Yes Tenofovir disoproxil Hepatitis B TA173 22/07/2009 Yes Cyclophosphamide CLL TA174 22/07/2009 Yes Fludarabine CLL TA174 22/07/2009 Yes phosphate Rituximab CLL TA174 22/07/2009 Yes Lenalidomide Mulitple myeloma TA171 18/06/2009 Yes Rivaroxaban VTE prophylaxis (post hip or knee replacement) TA170 22/04/2009 Yes Sunitinib Renal cell Ca (1st line) TA169 25/03/2009 Yes Oseltamivir Treatment of influenza TA168 25/02/2009 Yes Zanamivir Treatment of influenza TA168 25/02/2009 Yes Infliximab UC (acute exacerbations) TA163 17/12/2008 Yes Febuxostat Hyperuricaemia TA164 17/12/2008 Yes Strontium ranelate Secondary prevention TA162 26/11/2008 Yes Erlotinib NSCLC - treatment TA162 26/11/2008 Yes Oseltamivir Prevention of influenza TA158 24/09/2008 Yes

8 Zanamivir Prevention of influenza TA158 24/09/2008 Yes Dabigatran VTE prophylaxis (post hip or TA157 24/09/2008 Yes etexilate knee replacement) Ranibizumab AMD TA155 27/08/2008 Yes Entecavir Hepatitis B TA153 27/08/2008 Yes CSII (adults& Type 1 diabetes TA151 23/07/2008 Yes Children over 12 years & over) Adalimumab Psoriasis TA146 25/06/2008 Yes Cetuximab Head & neck Ca (locally TA145 25/06/2008 Yes advanced) Adalimumab Ankylosing spondylitis TA143 28/05/2008 Yes Etanercept Ankylosing spondylitis TA143 28/05/2008 Yes Darbopoetin Ca treatment-induced anaemia TA142 28/05/2008 Yes Epoetin alfa, beta & Ca treatment-induced TA142 28/05/2008 Yes delta anaemia Rituximab Follicular non-hodgkin's TA137 27/02/2008 Yes lymphoma Infliximab Psoriasis TA134 23/01/2008 Yes Pemetrexed Mesothelioma TA135 23/01/2008 Yes Ezetimibe Hypercholesterolaemia TA132 28/11/2007 Yes Adalimumab RA (first TNF) TA130 24/10/2007 Yes Etanercept RA (first TNF) TA130 24/10/2007 Yes Infliximab RA (first TNF) TA130 24/10/2007 Yes Bortezomib Relapsed Multiple myeloma TA129 24/10/2007 Yes

9 Natalizumab Multiple sclerosis TA127 22/08/2007 Yes Varenicline Smoking Cessation TA123 25/07/2007 Yes Carmustine Glioma TA121 27/06/2007 Yes (implant) Temozolomide Glioma TA121 27/06/2007 Yes Gemcitabine Metastatic breast Ca TA116 24/01/2007 Yes Paclitaxel Metastatic breast Ca TA116 24/01/2007 Yes Cinacalcet Secondary hyperparathyroidism TA117 24/01/2007 Yes Buprenorphine Managing Opiod Dependancy TA114 01/01/2007 Yes Methadone Managing Opiod Dependancy TA114 01/01/2007 Yes Naltrexone Managing Opiod Dependancy TA114 01/01/2007 Yes Anastrozole Breast Ca TA112 22/11/2006 Yes Exemestane Breast Ca TA112 22/11/2006 Yes Letrozole Breast Ca TA112 22/11/2006 Yes Doxorubicin hydrochloride Breast Ca TA109 21/09/2006 Yes Cyclophosphamide Early breast Ca TA109 21/09/2006 Yes Docetaxel Early breast Ca TA109 21/09/2006 Yes Ribavirin Hepatitis C (mild) TA106 26/08/2006 Yes Peginterferon alfa Hepatitis C (mild) TA106 26/08/2006 Yes

10 Trastuzumab Early breast Ca TA107 23/08/2006 Yes Etanercept Psoriasis TA103 26/07/2006 Yes Docetaxel Prostate Ca TA101 28/06/2006 Yes Basiliximab Renal transplantation TA99 26/04/2006 Yes (adults) Capecitabine Colon Ca TA100 26/04/2006 Yes Fluorouracil Colon Ca TA100 26/04/2006 Yes Oxaliplatin Colon Ca TA100 26/04/2006 Yes Peginterferon alfa Hepatitis B TA96 22/02/2006 Yes Adefovir dipivoxil Hepatitis B TA96 22/02/2006 Yes Carboplatin Ovarian Ca (advanced) TA91 01/05/2005 Yes Cisplatin Ovarian Ca (advanced) TA91 01/05/2005 Yes Doxorubicin Ovarian Ca TA91 01/05/2005 Yes hydrochloride (peg.lipsomal) Paclitaxel Ovarian Ca (advanced) TA91 01/05/2005 Yes Topotecan Ovarian Ca TA91 01/05/2005 Yes Basiliximab Renal transplantation (adolescents & children) TA85 22/09/2004 Yes Pimecrolimus Eczema TA82 01/08/2004 Yes Tacrolimus Eczema TA82 01/08/2004 Yes Clopidogrel ACS TA80 01/07/2004 Yes Zaleplon Insomnia TA77 01/04/2004 Yes Interferon alfa Hepatitis C (moderate-severe) TA75 01/01/2004 Yes

11 Peginterferon alfa Hepatitis C (moderate-severe) TA75 01/01/2004 Yes Ribavirin Hepatitis C (moderate-severe) TA75 01/01/2004 Yes Imatinib CML TA70 01/10/2003 Yes Cyclophosphamide Aggressive non-hodgkin's lymphoma TA65 01/09/2003 Yes Doxorubicin Non-Hodgkin's lymphoma TA65 01/09/2003 Yes hydrochloride Verteprofin PDT of AMD TA68 01/09/2003 Yes Rituximab Somatropin Aggressive non-hodgkin's lymphoma Growth hormone deficiency in adults TA65 TA64 01/09/2003 Yes 01/08/2003 Yes Capecitabine Metastatic colorectal Ca TA61 01/05/2003 Yes Tegafur with uracil Metastatic colorectal Ca TA61 01/05/2003 Yes Paclitaxel Ovarian Ca TA55 01/01/2003 Yes Insulin glargine Type 1&2 diabetes TA53 01/12/2002 Yes Alteplase Acute MI TA52 01/10/2002 Yes Reteplase Acute MI TA52 01/10/2002 Yes Streptokinase Acute MI TA52 01/10/2002 Yes Tenecteplase Acute MI TA52 01/10/2002 Yes Etanercept Juvenile arthritis TA35 01/03/2002 Yes Gemcitabine Pancreatic Ca TA25 01/05/2001 Yes Temozolomide Brain cancer TA23 01/04/2001 Yes Riluzole MND TA20 01/01/2001 Yes

12 Drug Indication NICE Approval Release Date Pemetrexed Aflibercept Lung cancer (non small cell, non squamous) Colorectal cancer(metastatic) TA 309 TA307 23/4/2014 No 23/3/14 No for Local Use Canakinumab Juvenile idiopathic arthritis (systemic) TA302 Terminated Appraisal 27/11/2013 No Bosutinib Leukaemia (chronic myeloid) TA299 27/11/2013 No Crizotinib Lung CA TA296 25/09/2013 No Everolimus Advanced breast Ca TA295 not 28/08/2013 No Pegloticase Servere debilitating chronic tophaceous gout TA291 26/06/2013 No

13 Ruxolitinib Bevacizumab in combo with Gemcitabine & Carboplatin Disease-related splenomegaly or symptoms in adults with myelofibrosis 1st recurrence of platinum-sensitive advanced ovarian cancer TA289 TA285 26/06/2013 No 22/05/2013 No Bevacizumab in combo with Paclitaxel & Carboplatin 1st line treatment of advanced ovarian cancer TA284 22/05/2013 No Loxapine inhalation Acute agitation & disturbed behaviours associated with schizophrenia & bipolar disorder TA286 Terminated Appraisal Canakinumab CAPS TA281 Terminated Appraisal Methylnalrexone opioid-induced bowel TA277 Terminated dysfunction in people Appraisal with advanced illness receiving palliative care Vinflunine TCCU TA272 Fluocinolone implant Tadalafil Diabetic macular oedema Benign Prostatic Hyperplasia TA271 Decitabine AML TA270 Bevacizumab Adalimumab Lapatinib Trastuzumab Adv/Metastatic breast Ca 1st line Moderate-severe UC (2nd line) HER2 +ve metastatic breast Ca HER2 +ve metastatic breast Ca 22/05/2013 No 24/04/2013 No 27/03/2013 No 23/01/2013 No 23/01/2013 No TA273 Terminated 23/01/2013 No TA263 TA262 TA257 TA257 12/12/2012 No 22/08/2012 No 27/06/2012 No 27/06/2012 No 27/06/2012 No

14 Cabazitaxel Metastatic prostate Ca TA255 11/05/2012 No Dasatinib CML 1st line TA251 25/04/2012 No Eribulin Locally advanced or metastatic breast cancer TA250 03/04/2012 No Bevacizumab Metastatic colorectal Ca 2nd Line TA242 25/01/2012 No Cetuximab Metastatic colorectal Ca (2nd line) TA242 25/01/2012 No Panitumumab Metastatic colorectal TA242 25/01/2012 No Ca (2nd line) Dasatinib CML dasatinib, nilotinib, imatinib (intolerant, resistant) TA241 not 13/01/2012 No Imatinib CML dasatinib, TA241 13/01/2012 No nilotinib, imatinib (intolerant, resistant) Fulvestrant Breast Ca TA239 14/12/2011 No Panitumumab Metastatic colorectal TA240 Terminated Ca (2nd line) Bendamustine Indolent NHL TA206 Agomelatine Depression TA231 Erlotinib NSCLC - maintenance TA227 Golimumab Cilostazol Inositol nicotinate RA (methotrexatenaïve) Intermiittent claudication associated with peripheral vasular disease Intermiittent claudication associated with TA224 Terminated TA223 TA223 14/12/2011 No 27/10/2011 No 27/07/2011 No 29/06/2011 No 22/06/2011 No 25/05/2011 No 25/05/2011 No

15 peripheral vasular disease Pentoxifylline Intermiittent claudication associated with peripheral vasular disease TA223 Trabectedin Relapsed ovarian Ca TA222 Everolimus Advanced RCC (2nd TA219 line) 25/05/2011 No 27/04/2011 No 19/04/2011 No Bevacizumab Metastatic breast Ca TA214 Raloxifene Primary prevention TA160 of osteoporosis 23/02/2011 No 26/01/2011 No Bevacizumab Trastuzumab Metastatic colorectal Ca HER2 +ve metastatic gastric Ca TA212 TA208 Ofatumumab CLL TA202 Fesoterodine Non-Hodgkin's lymphoma TA206 Imatinib GIST (adjuvant) TA196 Sorafenib Hepatocellular Ca TA189 Sorafenib Renal cell Ca TA178 Sunitinib Renal cell Ca (2nd TA178 line) Temsirolimus Renal cell Ca TA178 15/12/2010 No 24/11/2010 No 27/10/2010 No 27/10/2010 No 25/08/2010 No 26/05/2010 No 29/08/2009 No 29/08/2009 No 29/08/2009 No Bevacizumab Cetuximab Amantadine Renal cell Ca Head & neck Ca (recurrent or metastatic) Treatment of influenza TA178 TA172 TA168 29/08/2009 No 24/06/2009 No 25/02/2009 No

16 Amantadine Prevention of influenza TA158 24/09/2008 No Pegaptanib sodium AMD TA155 27/08/2008 No Telbivudine Hepatitis B TA154 27/08/2008 No Carmustine (implant) Glioblastoma multiforme TA149 25/06/2008 No Bevacizumab NSCLC TA148 Infliximab Ankylosing spondylitis TA143 Infliximab UC (sub-acute manifestations) TA140 Pemetrexed NSCLC (2nd line) TA124 25/06/2008 No 28/05/2008 No 23/04/2008 No 22/08/2007 No Fludarabine phosphate CLL TA119 28/02/2007 No Bevacizumab Cetuximab Fluorouracil Adv./metastatic colorectal Ca Metastatic colorectal Ca (2nd line) Colorectal Ca (metastatic) TA118 TA118 TA118 Paclitaxel Early breast Ca TA108 24/01/2007 No 24/01/2007 No 24/01/2007 No 27/09/2006 No Efalizumab Psoriasis TA103 Market Authorisation withdrawn 26/07/2006 No Drotrecogin alfa Sepsis TA84 terminated No Temsirolimus Mantle cell lymphoma TA207 Terminated No

NICE TA Adherence Check List

NICE TA Adherence Check List NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs

More information

2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee

2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee NICE Technology Appraisals - Time to Implementation Report - 18 December 2014 Produced by Tracy Steadman, Croydon Public Health Intelligence Team (C-PHIT), Croydon Council Date of Guidance Title of Guidance

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation NICE Technology Appraisals - Time to Implementation Report - 3 rd August 2015 Produced by Tracy Steadman, Croydon Public Health Intelligence Team, Croydon Council Date of Guidance Title of Guidance Summary

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

Cancer drug approvals for paediatric indications (n=43)

Cancer drug approvals for paediatric indications (n=43) Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December

More information

Royal Free London NHS Foundation Trust NICE Technology Appraisals and Drug Formulary Indications to date

Royal Free London NHS Foundation Trust NICE Technology Appraisals and Drug Formulary Indications to date Mar-00 TA1 Wisdom teeth removal impacted wisdom teeth should not be operated on Apr-00 TA2 Primary total hip replacement superseeded by MDA/2012/036 May-00 TA3 Ovarian cancer- taxanes Replaced by TA 55

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

More information

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2

More information

NICE-approved drugs available for use within the Trust

NICE-approved drugs available for use within the Trust NICE-approved drugs available for use within the Trust The following drugs have been recommended by NICE as treatment options for the indications noted below. They are listed in the Trust Medicines Formulary

More information

Appraisals. What is a NICE Technology Appraisal? Logo Here

Appraisals. What is a NICE Technology Appraisal? Logo Here Add A view your from Presentation NICE: Technology Title Here.. Appraisals Add Helen your Knight, name 9 and May organisation 2013 Logo Here What is a NICE Technology Appraisal? A review of clinical and

More information

Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016

Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016 Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016 Drugs can only be recharged to CCGs if used in line with local or national policies as outlined

More information

Working Formulary January 2013 Oncology Chemotherapy Regimens

Working Formulary January 2013 Oncology Chemotherapy Regimens Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy

More information

North of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440 This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks

More information

Hospital Prescribing: England 2012

Hospital Prescribing: England 2012 Hospital Prescribing: England 2012 Published 13 November 2013 We are the trusted source of authoritative data and information relating to health and care. www.hscic.gov.uk enquiries@hscic.gov.uk Author:

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients? NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland

More information

National Cancer Drugs Fund List Ver4.4

National Cancer Drugs Fund List Ver4.4 National Cancer Drugs Fund List Ver4.4 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following

More information

List of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013

List of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013 S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

National Cancer Drugs Fund List Ver4.0

National Cancer Drugs Fund List Ver4.0 National Cancer Drugs Fund List Ver4.0 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Contro VersDate Revision summary Ver 19 Mar 201 Update following Mar-14

More information

National Cancer Drugs Fund List Ver2.1

National Cancer Drugs Fund List Ver2.1 National Cancer Drugs Fund List Ver2.1 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

8. Malignant disease and immunosuppression

8. Malignant disease and immunosuppression 1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of

More information

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

April May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.

April May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion. April May 2014 Recommended for use within NHS Scotland April May 2014 aflibercept intravitreal (Eylea ) 954/14 For adults for the treatment of visual impairment due to macular oedema secondary to central

More information

Payment by Results 2013/2014 Drug and Device Exclusions

Payment by Results 2013/2014 Drug and Device Exclusions Payment by Results 2013/2014 Drug and Device Exclusions 1. Introduction The tariff payment system is nationally calculated averages. It is expected that against the tariff, providers will incur a deficit

More information

European consortium study on the availability of anti-neoplastic medicines

European consortium study on the availability of anti-neoplastic medicines European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

THE DUDLEY GROUP NHS FOUNDATION TRUST FOI

THE DUDLEY GROUP NHS FOUNDATION TRUST FOI THE DUDLEY GROUP NHS FOUNDATION TRUST FOI 011324 Question 2 Response shown in table below Question 4 - Please provide details of the number of applications for treatments used outside of their licensed

More information

Report of evidence-based assessments from Scottish Health Technologies Group August 2009

Report of evidence-based assessments from Scottish Health Technologies Group August 2009 Report of evidence-based assessments from Scottish Health Technologies Group August 2009 HTA Programme: Report no HSRE/SHTG/EBA Report/2009/003A Health Services Research & Effectiveness Unit CONTENTS

More information

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,

More information

North of England Cancer Drugs Approval Group (NECDAG) Cumulative Table of Decisions August 2012

North of England Cancer Drugs Approval Group (NECDAG) Cumulative Table of Decisions August 2012 Notes: This document is updated every 2 to 3 months; please check our website www.cancernorth.nhs.uk for latest version. This document does not all contain Interim Cancer Drugs Fund s, i.e. decisions made

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric

More information

IRB INDICATION Number ENROLLED

IRB INDICATION Number ENROLLED Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics

More information

Product Visual Guide

Product Visual Guide Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin

More information

Title Cancer Drug Phase Status

Title Cancer Drug Phase Status Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer

More information

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from to Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 04.07.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

List of Qualifying Conditions

List of Qualifying Conditions List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)

More information

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION

More information

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg

More information

Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN

Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)

More information

An D. Nguyen, MD Curriculum Vitae

An D. Nguyen, MD Curriculum Vitae OFFICE/ BUSINESS ADDRESS: Pacific Shores Medical Group 19582 Beach Blvd, Suite 212 Huntington Beach, CA 92648 Phone: (714) 252-9415 Fax: (714) 963-8407 ADDITIONAL OFFICE: 16300 Sand Canyon Avenue, Suite

More information

I. Diagnosis of the cancer type in CUP

I. Diagnosis of the cancer type in CUP Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:

More information

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016 Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

The following are J Code requirements

The following are J Code requirements The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based

More information

Our Clinical Trials. Oncology

Our Clinical Trials. Oncology Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine

More information

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from to Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 31.05.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial

More information

8. Malignant disease and immunosuppression

8. Malignant disease and immunosuppression 1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin

More information

8. Malignant disease and immunosuppression

8. Malignant disease and immunosuppression 1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)

More information

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017 NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within

More information

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA

More information

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing

Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing ABIRATERONE Prostate CA: castrate Prostate CA: castrate resistant metastatic dz Prostate

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Clinical Trials OPEN to ENROLLMENT

Clinical Trials OPEN to ENROLLMENT CNS 2014 Second Quarter Clinical Trials OPEN to ENROLLMENT GAB 101 (CNS THERAPEUTICS INC): Safety of 3 mg/ml Gablofen (baclofen injection) Delivered by Intrathecal Administration Using the Synchromed II

More information

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th

More information

Performance in Initiating Clinical Research Q2 2016/17

Performance in Initiating Clinical Research Q2 2016/17 Performance in Initiating Clinical Research Q2 2016/17 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application

More information

World Health Organization: Essential Medicines and Devices for Cancer:

World Health Organization: Essential Medicines and Devices for Cancer: World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health

More information

CancerPACTtm. Cancer Patients Alliance for Clinical Trials. Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011

CancerPACTtm. Cancer Patients Alliance for Clinical Trials. Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011 CancerPACTtm Cancer Patients Alliance for Clinical Trials Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011 Solid Tumors 1. Breast... 2 2. Central Nervous System... 4 3. Gastrointestinal...

More information

New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here

New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation. Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.04 Subject: Avastin Page: 1 of 8 Last Review Date: December 3, 2015 Avastin Description Avastin (bevacizumab)

More information

For Health Professionals Who Care For Cancer Patients

For Health Professionals Who Care For Cancer Patients April 2018 Volume 21, No. 4 For Health Professionals Who Care For Cancer Patients Inside This Issue: Editor s Choice New Programs: Palbociclib for Metastatic Breast Cancer, Adjuvant Capecitabine for Breast

More information

Avastin (bevacizumab)

Avastin (bevacizumab) Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin

More information

Targeted Cancer Therapies

Targeted Cancer Therapies Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen

More information

Cancer-Drug Associations: A Complex System

Cancer-Drug Associations: A Complex System Cancer-Drug Associations: A Complex System Ertugrul Dalkic 1,2,3, Xuewei Wang 1,4, Neil Wright 1,5, Christina Chan 1,2,3,4,6,7 * 1 Center for Systems Biology, Michigan State University, East Lansing, Michigan,

More information

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information

Target date to recruit patients agreed? Target range. maximum. minimum. Date. 5 Agreed 26/01/ /11/2015 Recruitment Finished.

Target date to recruit patients agreed? Target range. maximum. minimum. Date. 5 Agreed 26/01/ /11/2015 Recruitment Finished. No REC Reference IRAS No Title Target number of agreed? Target range minimum Target range maximum Target date to recruit agreed? Planned Recruitment end date Total no of recruited at the agreed target

More information

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in

More information